Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

NOVO NORDISK, INC.

Filed by ARNOLD & PORTER KAYE SCHOLER LLP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 18, 2025
Income
$80,000.00
Expenses
Not reported
Filing UUID
27d55ed0-c13b-4a4b-a45e-c5d4da41fbe7
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

Issues related to pharmacy benefit managers (PBMs) and the 340B Program.

HCR · Health Issues

Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.

MMM · Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).

Literal federal measure citations: H.R. 4818, S. 2407

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.